- Rigel Pharma ( NASDAQ: RIGL ) is trading 17% higher after the company reported Q2 result that beat estimates, helped by higher sales of Tavalisse to treat adults with low platelet counts due to chronic immune thrombocytopenia.
- The company reported Q2 GAAP EPS of -$0.08, that beats estimate by $0.04, while Revenue rose 13.5% Y/Y to $29.82M, and beat estimates by $6.17M.
- Tavalisse net product sales of $18.6M increased by 9%, compared to $17.1M, a year earlier.
- Contract revenues from collaborations during the quarter was $11.3M.
- Rigel has cash of $89.2M.
For further details see:
Rigel rises 17% on strong Q2 result